Current Activities

Studies

No.

Participated Studies

Criteria

Hospitals

1

A randomized double-blind, double-dummy parallel group study to compare the efficacy and safety of fluticasone propionate / formoterol fumarate (flutiform®)500/20 µg BID and 250/10 µg BID versus salmeterol/fluticasone (Seretide®) 50/500 µg BID in subjects with chronic obstructive pulmonary disease (COPD)

Inclusion:

  1. COPD patients with FEV1/FVC ≤ 0.70
  2. FEV1 ≤60 %
  3. COPD exacerbation in recent one year

NTUH、VGHTPE、CTH、VGHTC、CMUH、EDAH

2

Phase 3: A 52-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect of tiotropium+olodaterol with fixed dose  (2.5 µg / 5µg and 5 µg / 5 µg)  (by Respimat®) with seperate substances (2.5 µg and 5 µg tiotropium, 5 µg olodaterol) in  COPD patients

 

NTUH、FEMH、CMUH、CGMH, Kaohsiung

3

Phase 3: A 52-week treatment,  double-blind, randomized, placebo controlled, parallel-group trial for patients with chronic obstructive pulmonary disease (COPD), with long-term   fixed component of inhaled β agonist and corticosteroid (LABA / ICS) treatment patients, to assess the impact of 500 micrograms (μg) Roflumilast to exacerbation rate

 

VGHTPE、VGHTC、CCH

Other studies
1. COPD phenotypes in ICS therapy
2.Placenta Growth Factor Gene Polymorphism in COPD
3.Differentiate Chronic bronchitis and Emphysema via angiogenetic growth factors
4.The relationships between phenotypes and genotypes in patients with COPD
5.Establish a composite index to predict recent mortality in COPD patient
6.The Role of Bactericidal/ permeability-increasing Protein in Men with Chronic Obstructive Pulmonary Disease
7.Dose Response relation between serum surfactant protein-D, A and smoking amount among smokers with or without COPD
8.Cardiovascular risk reduction by Combination therapy in COPD patients